HIV type 1

Overview

Human immunodeficiency virus type 1 (HIV-1) is a lentivirus belonging to the family Retroviridae and the primary causative agent of acquired immunodeficiency syndrome (AIDS) worldwide. HIV-1 selectively targets CD4+ T lymphocytes, macrophages, and dendritic cells by binding the CD4 receptor in concert with co-receptors CCR5 or CXCR4, leading to progressive depletion of CD4+ effector memory T cells and systemic immune dysfunction. Upon cell entry, the viral reverse transcriptase enzyme converts the single-stranded RNA genome into double-stranded DNA, which is then integrated into the host genome by the viral integrase — a step that establishes a latent proviral reservoir impervious to current antiretroviral therapy (ART). HIV-1 is genetically diverse, with multiple subtypes and circulating recombinant forms distributed unevenly across global populations, complicating vaccine development and resistance surveillance.

Despite ART rendering HIV-1 a manageable chronic condition, it is not curative. Persistent proviral DNA in long-lived CD4+ T cells — including CD4+ effector memory T cells — underpins viral rebound upon treatment interruption. Chronic HIV-1 infection drives sustained immune activation, systemic inflammation marked by elevated TNF and dysregulation of B-cell populations, and end-organ complications affecting the brain, liver, cardiovascular system, and metabolic health. These sequelae occur even in virologically suppressed individuals on ART, making HIV-1 a continuing focus of intense basic, translational, and clinical research.

Recent Publications Summary

Recent studies on HIV type 1 have focused on both mechanistic virology and translational strategies for treatment and prevention. In ex vivo and cell-based work, the vaccine adjuvants monophosphoryl lipid A (MPLA) and the saponin-MPLA nanoparticle adjuvant (SMNP) were shown to trigger Toll-like receptor 4 (TLR4)-dependent cytokine production in monocyte-derived dendritic cells, with SMNP producing a stronger response than MPLA. Cytokines from adjuvant-stimulated dendritic cells induced HIV-1 transcription in a J-Lat latency model, and SMNP also induced cytokine responses in peripheral blood mononuclear cells from people with HIV-1. Importantly, SMNP substantially reduced the size of the inducible HIV-1 reservoir ex vivo, suggesting that adjuvant-driven immune activation may indirectly reverse latency 42475333Jul.

Several publications addressed antiretroviral treatment strategies and their broader consequences. A real-world 48-week study evaluated switching treatment-experienced HIV-1-infected patients from an integrase strand transfer inhibitor-based triple regimen to dolutegravir/lamivudine, focusing on efficacy and metabolic outcomes 42124360May. Another population-level analysis across seven southern and eastern African countries found no association between years of formal education and viral load suppression, challenging assumptions that educational attainment directly predicts chronic HIV treatment adherence in the region 42133676May. In addition, earlier initiation of antiretroviral therapy within 1 year after HIV-1 acquisition was examined in relation to non-AIDS-defining malignancy risk, with the study designed to assess whether earlier treatment reduces this risk while accounting for socioeconomic status 41206033Nov.

Other work explored host-virus interactions and immune selection. In KwaZulu-Natal, South Africa, HIV-1 was shown to exert strong HLA-B-dependent effects in the pre-ART era, where disease-susceptible alleles increased AIDS progression and vertical transmission, while protective alleles slowed progression and reduced transmission; these effects were markedly diminished in contemporary ART-era cohorts, indicating that antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles 42044322Apr. A separate study reported a gene-editing approach using hematopoietic stem and progenitor cells to generate B-cell “protein factories,” producing long-lasting therapeutic serum antibody levels against HIV-1 and demonstrating a platform for self-amplifying antibody delivery 41990179Apr. Another medicinal chemistry study used pharmacophore-oriented generative artificial intelligence to design non-nucleoside reverse transcriptase inhibitors, identifying compounds with potent activity against wild-type and drug-resistant HIV-1 mutants and improved cytotoxicity and pharmacokinetic properties 41909954Mar.

Additional publications broadened the clinical and research context of HIV type 1. A survey examined priorities, barriers, and experiences related to palliative and end-of-life care among people living with HIV 42134828May, while a qualitative study across 12 high-prevalence African countries highlighted burnout and self-care needs among health workers providing HIV care to children and adolescents 42139216May. A perspective on NIH HIV research outlined future directions for ending HIV in the United States by 2030 41628016Feb.

What Changes, What Holds

1. Adjuvant-driven immune activation may expose a latent vulnerability in HIV-1 reservoirs
NEW DIRECTION TLR4-stimulated dendritic-cell cytokines can wake latent HIV-1 in ex vivo models and, in the same setting, SMNP reduced the inducible reservoir size 42475333Jul. That does not overturn the baseline account of stable proviral persistence under ART, but it adds a potential latency-reversing mechanism tied to vaccine adjuvant biology. The practical implication is unsettled: immune activation may be useful for reservoir perturbation, yet it also raises caution about inflammatory contexts in people with HIV-1.

2. Treatment switching and social determinants refine, but do not replace, current ART expectations
REINFORCES Switching treatment-experienced patients to dolutegravir/lamivudine extends the baseline message that ART remains effective and clinically adaptable, while adding metabolic outcome data relevant to regimen choice 42124360May. The education analysis weakens any simple assumption that formal schooling predicts suppression, but it does not contradict the broader need for adherence support because the baseline never claimed education was determinative 42133676May. Earlier ART and malignancy risk remain an open prevention question rather than a change to HIV-1 biology.

3. ART-era selection pressure on HLA-B is being blunted, and durable antibody delivery is becoming more feasible
NEW DIRECTION HIV-1’s established role in shaping host immune selection is now seen as context dependent: the reported HLA-B effects were strong before ART but much weaker in contemporary cohorts, implying that treatment can interrupt natural selection pressures the baseline does not discuss 42044322Apr. In parallel, engineered B-cell “protein factories” suggest a new way to sustain anti-HIV-1 antibody exposure, but that is a delivery platform rather than a revision of viral pathogenesis 41990179Apr. The AI-designed inhibitors simply reinforce ongoing drug-discovery efforts 41909954Mar.

4. HIV care is being pushed to include end-of-life planning, workforce sustainability, and long-range policy goals
NEW DIRECTION Palliative and end-of-life care priorities add a clinical dimension the baseline does not cover, showing that HIV-1 management now extends beyond suppression and immune preservation into symptom relief and terminal care 42134828May. The burnout study similarly shifts attention to the workforce needed to deliver chronic HIV services, especially for children and adolescents 42139216May. The NIH perspective is policy-oriented rather than mechanistic, but together these papers broaden HIV-1 research from virology toward care systems and implementation 41628016Feb.

Overview update candidates: adjuvant-driven latency reversal and reservoir reduction; ART-era weakening of HLA-B selection pressure; expanded HIV care needs including palliative care and workforce sustainability.